Regeneron Pharmaceuticals/ US75886F1075 /
| 2024-04-18 9:59:58 PM | Chg. -7.49 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 893.66USD | -0.83% | 25,275 Turnover: 22.67 mill. |
-Bid Size: - | -Ask Size: - | 98.13 bill.USD | - | 24.13 |
Assets
| 2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 974.3090 | 1,594.1200 | 2,083.4210 | 2,358.6050 | 2,575.8000 | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | 460.1540 | 632.1620 | 864.2600 | 1,486.4940 | 1,755 | ||||||
| Fixed Assets | 1,704.3660 | 2,694.0370 | 3,793.2780 | 4,429.2560 | 5,286.9000 | ||||||
| Inventories | 128.8610 | 238.5780 | 399.3560 | 726.1380 | 1,151.2000 | ||||||
| Accounts Receivable | 739.3790 | 1,152.4890 | 1,343.3680 | 1,538.6420 | 1,723.7000 | ||||||
| Cash and Cash Equivalents | 648.7190 | 809.1020 | 535.2030 | 812.7330 | 1,467.7000 | ||||||
| Current Assets | 2,167.4610 | 2,915.0950 | 3,180.1880 | 4,335.0300 | 6,447.6000 | ||||||
| Total Assets | 3,871.8270 | 5,609.1320 | 6,973.4660 | 8,764.2860 | 11,734.5000 | ||||||
Liabilities
| 2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | - | - | - | 218.2000 | ||||||
| Long-term debt | 146.7730 | 362.9190 | 351.5690 | 703.4530 | 708.5000 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 1,329.5020 | 1,954.2950 | 2,524.2210 | 2,620.2080 | 2,977.2000 | ||||||
| Share Capital | .1020 | .1060 | .1080 | .1100 | .1000 | ||||||
| Total Equity | 2,542.3250 | 3,654.8370 | 4,449.2450 | 6,144.0780 | 8,757.3000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 3,871.8270 | 5,609.1320 | 6,973.4660 | 8,764.2860 | 11,734.5000 | ||||||
Income Statement
| 2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 2,819.5570 | 4,103.7280 | 4,860.4270 | 5,872.2270 | 6,710.8000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 838.4310 | 1,251.9160 | 1,330.7410 | 2,079.5910 | 2,534.4000 | ||||||
| Interest Income | -37.3720 | -14.2410 | -7.1950 | -25.1190 | -28.2000 | ||||||
| Income Before Taxes | 775.7470 | 1,225.0970 | 1,329.8150 | 2,078.5110 | 2,553.5000 | ||||||
| Income Taxes | -427.6730 | -589.0410 | -434.2930 | -880 | -109.1000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 348.0740 | 636.0560 | 895.5220 | 1,198.5110 | 2,444.4000 | ||||||
Per Share
Cash Flow
| 2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 743.1570 | 1,330.7800 | 1,473.3960 | 1,307.1120 | 2,195.1000 | ||||||
| Cash Flow from Investing Activities | -420.7770 | -907.6010 | -1,046.9040 | -1,005.1820 | -1,463 | ||||||
| Cash Flow from Financing | -209.2690 | -262.7960 | -700.3910 | -24.4000 | -77.1000 | ||||||
| Decrease / Increase in Cash | 113.1110 | 160.3830 | -273.8990 | 277.5300 | 655 | ||||||
| Employees | 2,925 | 4,300 | 5,400 | 6,200 | 7,400 | ||||||
